Webster Equity Partners inks $664m take-private of Lifecore Biomedical
Monday, September 28, 2026 · first reported by PE Hub and 2 others
Webster Equity Partners agreed to acquire Lifecore Biomedical (injectables CDMO) for up to $663.7M ($6.28/share cash + up to $160M CVRs); close expected Q4 2026.
- Also named
- Lifecore Biomedical
- Deal value
- $664M
- Asset class
- Private equity
- Geography
- North America
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
3 sources- Sycamore Partners agrees $8.9bn Boots exit to Wittington InvestmentsPE Hub +3
- Elliott, Siris weigh $2bn-plus sale of GigamonHedgeweek
- CVC ups Recordati take-private offer to €10.5bn after shareholder pushbackPrivate Equity Wire
- Old Ironsides, EnCap Flatrock’s Brazos seals $4.4bn Midland asset sale to ONEOKPE Hub
- Blackstone agrees $3.0bn sale of events business Clarion to InformaPE Hub
- Lovell Minnick, Carlyle AlpInvest-backed SRS Acquiom agrees to Pantarai acquisitionPE Hub